Anaphylm

The study enrolled healthy adult volunteers rather than participants experiencing an allergic reaction, so epinephrine exposure and hemodynamic response were measured under conditions that differ from an anaphylaxis emergency. It was open label and single center, no clinical efficacy endpoint such as symptom reversal was assessed, and the comparison with approved injectable products rested on pharmacokinetic bracketing rather than on a direct clinical outcome. Enrollment totalled 64 participants in the single-dose part and 36 in the repeat-dose part, and no registry record identifying the trial on ClinicalTrials.gov was located.

The study enrolled 36 adults with oral allergy syndrome at a single site and used a fruit allergen challenge to produce oral symptoms, a model of localized oral change rather than of systemic anaphylaxis. The design was open label and fixed sequence, the intramuscular comparator was given without allergen challenge, and Part 2 involved only 12 participants who crossed between single and repeat dosing. Symptom resolution was recorded after epinephrine administration without a placebo or no-treatment control, so the contribution of spontaneous resolution cannot be separated from the treatment effect.

Results are available only from a company topline announcement and a regulatory update, so the number of participants, the analysis sets, the statistical methods, and the confidence intervals around the reported geometric mean Cmax and median Tmax values have not been reported. The study was conducted in healthy volunteers rather than during allergic reactions, and the pharmacodynamic comparison for the top-of-tongue arm was described as a cross-study comparison against results from study AQ109301 rather than a within-study randomized comparison. No peer-reviewed publication or registry record for the study was located.

The comparison of 105 participants in the revised study with 166 participants in the earlier study is a comparison across two separate human factors studies rather than a randomized within-study comparison, and the user groups differed after the FDA recommended changes to them. Simulated-use testing measures handling of the packaging under observation and does not establish behaviour during an actual allergic reaction. Only topline counts have been released, with no report of the full set of use errors, the task analysis, or the participant characteristics, and the results have not been published or registered.

The study was open label, gave a single 12 mg dose with no comparator arm, and enrolled 32 participants aged 7 through 17 years who weighed at least 30 kg, so it provides no evidence for younger or lighter children, for whom 0.15 mg injectable products are used. Participants were dosed while well rather than during an allergic reaction. Results have been described only in a company announcement and the registry record carries no posted results, so individual pharmacokinetic parameters, variability, and the Oral Mucositis Assessment Scale findings are not publicly reported.

The trial was open label and enrolled healthy volunteers, so results describe epinephrine absorption and hemodynamic change in the absence of an allergic reaction. Reported results come from a company announcement and from an integrated analysis that pooled this trial with the earlier EPIPHAST trial, and the individual trial has no registry record and no separate peer-reviewed publication, so the number of participants, the analysis sets, and the variability around the reported Cmax and Tmax values are not available. Repeat dosing produced a mean Cmax of 2,958 pg/mL, well above the 911 pg/mL reported after two intramuscular doses, an exposure difference the FDA later required be justified on safety grounds.

EPIPHAST was an open-label adaptive crossover study in healthy adult volunteers conducted in Canada, and its parts used small numbers of doses, for example 48 doses per treatment in Part 2 and 21 to 23 doses per arm in the Part 3 hold-time comparison. Comparisons between Part 3 arms and the intramuscular injection were made against data generated in Part 2 rather than within the same treatment period, and formulations and configurations changed between parts, so results are not uniform across the study. No registry record for the study was located, and the numeric results are reported in company announcements rather than a full study publication.

The study enrolled 36 healthy adult volunteers who self-administered the film under supervision in a clinical setting, which does not reproduce administration during an allergic reaction. The design was open label with an intramuscular comparator given by a healthcare provider, and only median Tmax values and a qualitative statement of no statistical difference between the self-administered and provider-administered arms have been released; Cmax, area under the curve values, confidence intervals, and safety results were not reported. No registry record or peer-reviewed publication of the study was located.

The study enrolled 30 healthy adult volunteers and tested only water at three temperatures, lemon water and baking soda water, so it does not directly address the beverages and foods that the company noted fall between these acidity extremes. Pharmacodynamic results were not available at the time of the topline release, safety results were not reported, and only ratios relative to room temperature water were published, without absolute Cmax or area under the curve values or confidence intervals. No registry record or peer-reviewed publication of the study was located.

The study was a first-in-human single-ascending-dose evaluation in healthy volunteers with 6 to 8 dosings per formulation, so estimates of Cmax, Tmax, and area under the curve rest on very small numbers. It included no randomized injectable comparator arm; comparisons with EpiPen and Auvi-Q were drawn from previous and published studies rather than measured in the same participants. Two of the four formulations, including the formulation later taken forward, differed from the final commercial configuration, and no registry record or peer-reviewed publication of this individual study was located.